Completed PHASE1 INTERVENTIONAL 4-arm NCT02703350

A Study of LY900014 in Participants With Type 1 Diabetes on Insulin Injection Therapy

Pharmacokinetics, Glucodynamics, Safety, and Tolerability of LY900014 in Patients With Type 1 Diabetes Mellitus on Multiple Daily Insulin Injection Therapy

Sponsor: Eli Lilly and Company

Conditions Diabetes Mellitus, Type 1

Interventions Insulin Lispro LY900014

Updated 10 times since 2017 Last updated: Jun 10, 2020 Started: Mar 31, 2016 Primary completion: Jul 31, 2016 Completion: Jul 31, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02703350, this PHASE1 trial focuses on Diabetes Mellitus, Type 1 and remains completed. Sponsored by Eli Lilly and Company, it has been updated 10 times since 2016, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

10 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2023 — Jul 2024 [monthly]

Completed PHASE1
Dec 2022 — Jan 2023 [monthly]

Completed PHASE1
Jan 2021 — Dec 2022 [monthly]

Completed PHASE1

▶ Show 5 earlier versions

Jul 2020 — Jan 2021 [monthly]

Completed PHASE1
May 2020 — Jul 2020 [monthly]

Completed PHASE1
Jun 2018 — May 2020 [monthly]

Completed PHASE1
Feb 2017 — Jun 2018 [monthly]

Completed PHASE1
Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

Mar 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Eli Lilly and Company

Data source: Eli Lilly and Company

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Mainz, Germany